Study guide
11.2 Immunization & Travel Medicine
DHA Healthcare Professional Licensing Assessment - General Practitioner/Doctor Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Chronic Cardiovascular & Endocrine Disorders
1.1 Hypertension Management in Primary Care 1.2 Type 2 Diabetes Mellitus Management 1.3 Dyslipidemia & Thyroid Disorders
2 Chapter 2: Chronic Respiratory, Renal & Musculoskeletal Disorders
2.1 Asthma & COPD Maintenance 2.2 Chronic Kidney Disease 2.3 Chronic Musculoskeletal & Rheumatological Conditions
3 Chapter 3: Acute & Common Medical Problems
3.1 Common Infections in Primary Care 3.2 Anemia & Hematological Disorders 3.3 Acute Neurological Problems 3.4 Common Gastrointestinal Complaints
4 Chapter 4: Emergency Problems & Resuscitation
4.1 Cardiopulmonary Resuscitation & Shock 4.2 Acute Metabolic & Toxicological Emergencies 4.3 Trauma Assessment & Environmental Emergencies
5 Chapter 5: Common Pediatric Problems
5.1 Acute Pediatric Respiratory Infections 5.2 Febrile Seizures & Childhood Dehydration 5.3 Neonatal Jaundice & Pediatric Developmental Milestones
6 Chapter 6: Women's Health & Obstetric Care
6.1 Antenatal Care, Pre-eclampsia & Gestational Diabetes 6.2 Contraception & Menopause 6.3 Common Gynecological Conditions
7 Chapter 7: Common Surgical Problems
7.1 Acute Abdomen 7.2 Hernias, Hemorrhoids & Testicular Torsion 7.3 Abdominal Aortic Aneurysm & Urological Emergencies
8 Chapter 8: Common Psychiatric Problems
8.1 Mood & Anxiety Disorders 8.2 Psychosis, Delirium & Substance Use 8.3 Suicide Risk Assessment & Crisis Intervention
9 Chapter 9: Common Eye & ENT Problems
9.1 Acute Red Eye, Glaucoma & Uveitis 9.2 Otitis Media, Epistaxis & Vertigo 9.3 Common Upper Respiratory ENT Infections
10 Chapter 10: Common Dermatology Problems
10.1 Acne & Psoriasis 10.2 Eczema, Dermatitis & Skin Infections 10.3 Skin Infestations & Cutaneous Malignancies
11 Chapter 11: Family Medicine Concepts & Health Promotion
11.1 Patient-Centered Care & Continuity 11.2 Immunization & Travel Medicine 11.3 Smoking Cessation & Lifestyle Medicine
12 Chapter 12: Screening & Preventive Medicine
12.1 Cancer Screening 12.2 Cardiovascular & Metabolic Risk Screening
13 Chapter 13: Epidemiology, EBM, Ethics & UAE Regulations
13.1 Basic Epidemiology & Outbreak Measures 13.2 Evidence-Based Medicine & Study Designs 13.3 Professionalism, Ethics & UAE Regulations
11.2 Immunization & Travel Medicine
Key Takeaways Explain This Topic AI
The childhood schedule begins with BCG and HepB at birth, followed by primary hexavalent and PCV series.
Adults require annual influenza vaccination, a Tdap booster every 10 years, and Tdap during every pregnancy.
PCV20 or PCV15 followed by PPSV23 is indicated for adults aged >= 65 or younger adults with high-risk conditions.
Mefloquine is contraindicated in patients with psychiatric history, and Yellow Fever is contraindicated in immunodeficient individuals.
Last updated: July 2026
Immunization & Travel Medicine
Immunizations represent one of the most cost-effective and impactful public health interventions in modern medicine. In primary care, family physicians must manage routine pediatric and adult immunization schedules, assess travel-related health risks, and prescribe appropriate chemoprophylaxis.
Childhood Vaccination Schedules
Childhood immunization schedules aim to provide early protection against life-threatening infectious diseases. The UAE Ministry of Health and Prevention (MOHAP) and Dubai Health Authority (DHA) align their National Immunization Program closely with World Health Organization (WHO) standards.
Key Pediatric Vaccine Milestones:
At Birth : BCG (Bacille Calmette-Guérin) vaccine to protect against tuberculous meningitis and miliary tuberculosis, and the Hepatitis B (HepB) vaccine first dose.
2, 4, and 6 Months : Primary series of Hexavalent vaccine (DTaP-HepB-IPV-Hib: Diphtheria, Tetanus, pertussis, Hepatitis B, Inactivated Polio Vaccine, and Haemophilus influenzae type b) and Pneumococcal Conjugate Vaccine (PCV) . A Rotavirus vaccine (oral) is also administered.
12 Months : MMR (Measles, Mumps, Rubella) first dose, Varicella first dose, and Meningococcal Conjugate Vaccine (MCV4) .
18 Months : Booster doses of DTaP-IPV-Hib, PCV, MMR, Varicella, and Hepatitis A.
School Entry (4 to 6 Years) : Boosters of DTaP, Polio (OPV or IPV), MMR, and Varicella.
Adult Vaccination Guidelines
Adult vaccination is critical to maintain waning immunity, protect vulnerable populations (cocooning), and address age- or comorbidity-related susceptibility.
Standard Adult Schedule:
Influenza : Annual administration of the inactivated quadrivalent influenza vaccine is recommended for all individuals aged ≥ \ge ≥ 6 months, particularly pregnant women, elderly individuals, and those with chronic medical conditions.
Tetanus, Diphtheria, Pertussis (Tdap) : A single dose of Tdap should be given to adults who have not previously received it. A Td booster (or Tdap) is recommended every 10 years . Pregnant women should receive Tdap during every pregnancy (ideally between 27 and 36 weeks gestation ) to optimize transplacental transfer of pertussis antibodies to the neonate.
Pneumococcal Vaccine :
Healthy adults ≥ \ge ≥ 65 years : A single dose of PCV20 OR a single dose of PCV15 followed by PPSV23 at least 1 year later.
Adults aged 19–64 with high-risk conditions (e.g., chronic heart, lung, or liver disease, diabetes, alcoholism, smoking): PCV20 alone OR PCV15 followed by PPSV23.
Immunocompromised adults aged 19-64 (e.g., HIV, chronic renal failure, nephrotic syndrome, asplenia): PCV20 alone OR PCV15 followed by PPSV23 (with shortened interval of 8 weeks).
Herpes Zoster (Shingles) : The recombinant zoster vaccine ( Shingrix ) is recommended as a 2-dose series (separated by 2-6 months) for all adults aged ≥ \ge ≥ 50 years and immunocompromised adults aged ≥ \ge ≥ 19 years , regardless of prior history of shingles or varicella vaccination.
Human Papillomavirus (HPV) : Recommended for all adolescents at age 11 or 12, and catch-up vaccination for all adults through age 26 . Shared clinical decision-making is recommended for some adults aged 27 through 45 years who are not adequately vaccinated.
Travel Vaccine Indications
Pre-travel consultations should occur at least 4 to 6 weeks prior to departure to allow adequate time for vaccine series completion and immune response development.
Vaccine Indication Special Considerations
Yellow Fever Required for entry to certain countries in sub-Saharan Africa and tropical South America, or if traveling from an endemic zone. Must be administered at an approved Yellow Fever vaccination center. Contraindicated in infants <9 months, pregnant/lactating women, and immunocompromised individuals due to its live-attenuated nature.
Meningococcal ACWY Mandatory for pilgrims participating in the Hajj or Umrah in Saudi Arabia. Recommended for travel to the "meningitis belt" of sub-Saharan Africa. Proof of vaccination (quadrivalent conjugate vaccine within the last 3-5 years) is required for visa issuance.
Hepatitis A Recommended for all travelers to countries with intermediate-to-high endemicity (most low- and middle-income nations). Administer first dose prior to departure; second dose at least 6 months later for long-term protection.
Typhoid Recommended for travelers to South Asia, Southeast Asia, Africa, and Central/South America, especially those visiting friends/relatives or venturing off the beaten path. Available as an oral live-attenuated vaccine (4 capsules taken every other day) or an intramuscular capsular polysaccharide injection.
Rabies Recommended for travelers spending significant time outdoors in endemic areas, children, or those with occupational exposure (veterinarians, wildlife handlers). Pre-exposure prophylaxis (PrEP) simplifies post-exposure management (does not eliminate the need for post-exposure care but removes the need for Rabies Immunoglobulin [RIG]).
Malaria Chemoprophylaxis
Malaria prevention relies on the "ABCD" approach: A wareness of risk, B ite prevention (DEET 30-50%, permethrin-treated gear), C hemoprophylaxis, and D iagnosis (seeking prompt medical evaluation for fever after travel).
The choice of chemoprophylaxis depends on the geographic region, drug resistance patterns, patient comorbidities, and pregnancy status:
Atovaquone-Proguanil (Malarone)
Mechanism : Inhibits mitochondrial electron transport.
Dosing : Daily. Start 1–2 days before travel, daily during travel, and 7 days after return .
Advantages : Well tolerated; short post-travel course.
Disadvantages : Expensive; contraindicated in severe renal impairment (Creatinine Clearance < 30 mL/min) and pregnancy.
Doxycycline
Mechanism : Inhibits protein synthesis (tetracycline).
Dosing : Daily. Start 1–2 days before travel, daily during travel, and 4 weeks after return .
Advantages : Inexpensive; protects against other infections (leptospirosis, rickettsia).
Disadvantages : Causes photosensitivity, pill-induced esophagitis (must take with fluids and stay upright), and vaginal candidiasis. Contraindicated in children < 8 years and pregnant women.
Mefloquine
Mechanism : Unknown, active against asexual erythrocytic stages.
Dosing : Weekly. Start 2–3 weeks before travel, weekly during travel, and 4 weeks after return .
Advantages : Safe in pregnancy (first-line in second/third trimesters); weekly dosing.
Disadvantages : Contraindicated in patients with psychiatric conditions (depression, generalized anxiety disorder, schizophrenia) or cardiac conduction abnormalities due to risk of neuropsychiatric side effects and QT prolongation.
Chloroquine
Mechanism : Prevents polymerization of toxic heme.
Dosing : Weekly. Start 1–2 weeks before travel, weekly during travel, and 4 weeks after return .
Usage : Only indicated for travel to areas without chloroquine-resistant Plasmodium falciparum (e.g., parts of the Caribbean, Central America west of the Panama Canal, and parts of the Middle East). Safe in pregnancy.